Committee Recommends Continuation of Phase III Trial of Picoplatin

Poniard Pharmaceuticals, Inc. announced that the independent Data Monitoring Committee, after review of available information regarding the efficacy, safety and quality of trial conduct, recommends that the SPEAR trial continue.
TradingMarkets